Cognitive Impairments in Patients With Schizophrenia Displaying Preserved and Compromised Intellect
2000/09/01 by Thomas W. Weickert, Terry E. Goldberg, James M. Gold +3 · 29 citations
Medicine · Psychology · #Schizophrenia research and treatment #Cognitive Functions and Memory #Down syndrome and intellectual disability research
paper · doi:10.1001/archpsyc.57.9.907
Abstract
BACKGROUND: Although intellectual and neurocognitive deficits accompany schizophrenia, there are inconsistencies in the literature concerning issues of intellectual decline, premorbid deficits, a modal deficit pattern, and preserved abilities. METHODS: A battery of neuropsychological tests was administered once to 117 consecutively admitted patients with chronic schizophrenia and a group of 27 healthy control subjects to examine patterns of premorbid and current intellect (measured by means of reading scores and IQ, respectively) and the attendant cognitive profiles in schizophrenia using classification methods based on clinically derived (IQ levels) and atheoretical (cluster) techniques. RESULTS: Sixty patients (51%) with schizophrenia who displayed a general intellectual decline of 10 points or greater from estimated premorbid levels also exhibited deficits of executive function, memory, and attention. Twenty-eight patients (23%) with consistently low estimated premorbid intellect and current intellectual levels who displayed no evidence of IQ decline exhibited language and visual processing deficits in addition to deficits present in the intellectually declining group. The remaining 29 patients (25%) who displayed average estimated premorbid intellectual levels did not show IQ decline and exhibited a cognitive profile similar to normal, with the exception of executive function and attention impairment. Atheoretical analyses support the findings from clinically derived subgroups. CONCLUSIONS: These results suggest that IQ decline, although modal in schizophrenia, is not universally characteristic and that executive function and attention deficits may be core features of schizophrenia, independent of IQ variations.
Cited by
- Adjunctive canakinumab reduces peripheral inflammation markers and improves positive symptoms in people with schizophrenia and inflammation: A randomized control trial
- Pragmatic Language and Theory of Mind Deficits in People with Schizophrenia and Their Relatives
- Social Cognition Psychometric Evaluation: Results of the Initial Psychometric Study
- Functional significance of preserved affect recognition in schizophrenia
- Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. [europepmc]
- Neuropsychological profiles delineate distinct profiles of schizophrenia, an interaction between memory and executive function, and uneven distribution of clinical subtypes. [europepmc]
- DTNBP1 genotype influences cognitive decline in schizophrenia. [europepmc]
- Cognitive heterogeneity in schizophrenia. [europepmc]
- Genetic variation in catechol-O-methyltransferase: effects on working memory in schizophrenic patients, their siblings, and healthy controls. [europepmc]
- An investigation of the relationship between activation of a social cognitive neural network and social functioning. [europepmc]
- Neuropsychological near normality and brain structure abnormality in schizophrenia. [europepmc]
- Magnetoencephalographic gamma power reduction in patients with schizophrenia during resting condition. [europepmc]
- IQ trajectory, cognitive reserve, and clinical outcome following a first episode of psychosis: a 3-year longitudinal study. [europepmc]
- Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT(1A) receptors but not 5-HT(2A) receptors. [europepmc]
- Neuropsychological profiles in individuals at clinical high risk for psychosis: relationship to psychosis and intelligence. [europepmc]
- Gray matter volume reduction in rostral middle frontal gyrus in patients with chronic schizophrenia. [europepmc]
- Impact of neurocognition on social and role functioning in individuals at clinical high risk for psychosis. [europepmc]
- Progressive gray matter loss and changes in cognitive functioning associated with exposure to herpes simplex virus 1 in schizophrenia: a longitudinal study. [europepmc]
- Developmental changes in human dopamine neurotransmission: cortical receptors and terminators. [europepmc]
- Rethinking schizophrenia in the context of normal neurodevelopment. [europepmc]
- Neuropsychological decline in schizophrenia from the premorbid to the postonset period: evidence from a population-representative longitudinal study. [europepmc]
- Social cognition psychometric evaluation (SCOPE) in people with early psychosis: A preliminary study. [europepmc]
- Prefrontal-Thalamic Anatomical Connectivity and Executive Cognitive Function in Schizophrenia. [europepmc]
- Self-assessment of social cognitive ability in schizophrenia: Association with social cognitive test performance, informant assessments of social cognitive ability, and everyday outcomes. [europepmc]
- A Comparison of Methamphetamine-Induced Psychosis and Schizophrenia: A Review of Positive, Negative, and Cognitive Symptomatology. [europepmc]
- Genetic Overlap between General Cognitive Function and Schizophrenia: A Review of Cognitive GWASs. [europepmc]
- Brain morphological and functional features in cognitive subgroups of schizophrenia. [europepmc]
- Distinct Polygenic Score Profiles in Schizophrenia Subgroups With Different Trajectories of Cognitive Development. [europepmc]
- Electrophysiological measures from human iPSC-derived neurons are associated with schizophrenia clinical status and predict individual cognitive performance. [europepmc]
Related